Total Payments
$2,854
2020 Payments
$11.26
Companies
25
Transactions
172
Medicare Patients
881
Medicare Billing
$82,132
Payment Breakdown by Category
Food & Beverage$2,843 (99.6%)
Education$11.26 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,843 | 171 | 99.6% |
| Education | $11.26 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $407.98 | 30 | $0 (2018) |
| ACADIA Pharmaceuticals Inc | $407.55 | 25 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $386.99 | 23 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $277.37 | 15 | $0 (2018) |
| UCB, Inc. | $229.30 | 16 | $0 (2018) |
| EMD Serono, Inc. | $145.93 | 8 | $0 (2018) |
| Promius Pharma LLC | $112.44 | 7 | $0 (2018) |
| GE Healthcare | $106.41 | 3 | $0 (2018) |
| GENZYME CORPORATION | $102.44 | 5 | $0 (2019) |
| Avanir Pharmaceuticals, Inc. | $93.01 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $11.26 | 1 | CSL Behring ($11.26) |
| 2019 | $161.58 | 11 | Sunovion Pharmaceuticals Inc. ($145.79) |
| 2018 | $1,327 | 73 | Sunovion Pharmaceuticals Inc. ($205.18) |
| 2017 | $1,354 | 87 | ACADIA Pharmaceuticals Inc ($243.54) |
All Payment Transactions
172 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/28/2020 | CSL Behring | Hizentra (Biological) | Education | In-kind items and services | $11.26 | General |
| Category: Immunology | ||||||
| 10/30/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $11.00 | General |
| Category: CNS | ||||||
| 09/03/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $11.00 | General |
| Category: CNS | ||||||
| 06/24/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: CNS | ||||||
| 06/05/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: CNS | ||||||
| 05/15/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $13.19 | General |
| Category: CNS | ||||||
| 05/01/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: CNS | ||||||
| 04/10/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: CNS | ||||||
| 02/21/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: CNS | ||||||
| 01/29/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: CNS | ||||||
| 01/21/2019 | GENZYME CORPORATION | LEMTRADA (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 01/09/2019 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: CNS | ||||||
| 12/17/2018 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: CNS | ||||||
| 12/12/2018 | EMD Serono, Inc. | Rebif (Biological) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: Neurology | ||||||
| 12/11/2018 | Supernus Pharmaceuticals, Inc. | OXTELLAR XR (Drug) | Food and Beverage | Cash or cash equivalent | $5.45 | General |
| Category: AED | ||||||
| 12/05/2018 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $5.42 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/14/2018 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $10.75 | General |
| Category: Neuroscience | ||||||
| 11/07/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $5.54 | General |
| Category: AED | ||||||
| 10/29/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.87 | General |
| Category: AED | ||||||
| 10/17/2018 | Supernus Pharmaceuticals, Inc. | OXTELLAR XR (Drug) | Food and Beverage | Cash or cash equivalent | $5.95 | General |
| Category: AED | ||||||
| 10/08/2018 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Immunology and Neurology | ||||||
| 10/05/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $5.93 | General |
| Category: NEUROSCIENCE | ||||||
| 09/12/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $6.05 | General |
| Category: AED | ||||||
| 08/21/2018 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $11.85 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 216 | 282 | $79,348 | $19,631 |
| 2022 | 6 | 216 | 282 | $84,460 | $22,060 |
| 2021 | 6 | 251 | 353 | $92,521 | $22,821 |
| 2020 | 7 | 198 | 220 | $78,665 | $17,620 |
Total Patients
881
Total Services
1,137
Medicare Billing
$82,132
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 76 | 76 | $34,956 | $9,686 | 27.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 48 | 56 | $18,040 | $5,449 | 30.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 54 | 112 | $7,952 | $2,593 | 32.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 25 | 25 | $15,225 | $1,056 | 6.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 13 | $3,175 | $847.14 | 26.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 59 | 59 | $27,785 | $7,032 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 61 | 68 | $22,564 | $6,715 | 29.8% |
| 95726 | Measurement of brain wave activity with video (veeg), more than 84 hours with review and report by health care professional | Facility | 2022 | 13 | 14 | $6,720 | $4,430 | 65.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 49 | 107 | $7,597 | $2,467 | 32.5% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 22 | 22 | $13,398 | $928.38 | 6.9% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 12 | 12 | $6,396 | $487.63 | 7.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 74 | 78 | $25,158 | $7,611 | 30.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 51 | 51 | $23,205 | $6,940 | 29.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 68 | 165 | $11,715 | $4,170 | 35.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $7,168 | $2,349 | 32.8% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Facility | 2021 | 30 | 31 | $18,879 | $1,263 | 6.7% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 12 | 12 | $6,396 | $487.89 | 7.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 60 | 72 | $23,112 | $5,347 | 23.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 27 | $12,473 | $3,466 | 27.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 19 | 20 | $8,960 | $3,030 | 33.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 37 | 43 | $10,345 | $2,266 | 21.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 21 | 21 | $7,881 | $1,965 | 24.9% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Facility | 2020 | 22 | 22 | $13,398 | $1,013 | 7.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 12 | 15 | $2,496 | $532.01 | 21.3% |
About Dr. Amer Awad, MD
Dr. Amer Awad, MD is a Neurology healthcare provider based in Gonzales, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1275735037.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amer Awad, MD has received a total of $2,854 in payments from pharmaceutical and medical device companies, with $11.26 received in 2020. These payments were reported across 172 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($2,843).
As a Medicare-enrolled provider, Awad has provided services to 881 Medicare beneficiaries, totaling 1,137 services with total Medicare billing of $82,132. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Gonzales, LA
- Active Since 06/04/2007
- Last Updated 10/31/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1275735037
Products in Payments
- NUPLAZID (Drug) $407.55
- APTIOM (Drug) $386.99
- OXTELLAR XR (Drug) $227.02
- Vimpat (Drug) $217.26
- TROKENDI XR (Drug) $180.96
- Rebif (Biological) $145.93
- GILENYA (Drug) $127.79
- Zembrace (Drug) $112.44
- NUEDEXTA (Drug) $93.01
- Fycompa (Drug) $88.38
- LEMTRADA (Drug) $80.17
- NAMZARIC (Drug) $74.90
- ACTHAR (Biological) $62.22
- Gamunex-C (Biological) $56.38
- TYSABRI (Biological) $53.36
- TREXIMET (Drug) $50.55
- Cambia (Drug) $39.51
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $27.85
- COPAXONE (Drug) $25.61
- AUBAGIO (Drug) $22.27
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.